Panchalee Satpanich1, Wanjak Pongsittisak2, Siriporn Manavathongchai3. 1. Rheumatology Division, Department of Internal Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, 10300, Thailand. satpanichp@gmail.com. 2. Nephrology and Renal Replacement Therapy Division, Department of Internal Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand. 3. Rheumatology Division, Department of Internal Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, 10300, Thailand.
Abstract
OBJECTIVE: Currently available guidelines on urate-lowering therapy (ULT) initiation in acute gout flare are conflicting. We compared the time to complete resolution of acute gout flare between early and late allopurinol initiation. METHODS: This 28-day, randomized controlled, open-label trial included patients with crystal-proven gout who were presented with acute gout flare within 72 h of arthritis onset. Exclusion criteria were advanced renal failure, ongoing ULT, and presence of the HLA-B*5801 allele. Allopurinol was used on days 1 and 14 in early and late groups, respectively. Primary outcome was time to complete arthritis resolution, and secondary outcomes were time to clinical resolution; arthritis relapse; laboratory parameters; and adverse events. RESULTS: One hundred seventeen patients were randomized to early and late allopurinol groups (n = 59 and 58, respectively). One patient in each group was lost to follow-up; therefore, 115 patients were included in the modified intention-to-treat analysis. Baseline characteristics were comparable between the groups. The median time to complete resolution was not significantly different between the early and late allopurinol groups (6 [5-14] and 6 [5-7] days, respectively; p = 0.14). The median time to clinical resolution was 4 [3-6] days in both groups (p = 0.12). Other secondary outcomes were not significantly different. Serious adverse events did not occur in either group. CONCLUSIONS: Early allopurinol initiation during an acute gout flare did not lead to significant changes in time to resolution, flare recurrence, and inflammatory markers. Key Points • Allopurinol Initiation in Gout.
OBJECTIVE: Currently available guidelines on urate-lowering therapy (ULT) initiation in acute gout flare are conflicting. We compared the time to complete resolution of acute gout flare between early and late allopurinol initiation. METHODS: This 28-day, randomized controlled, open-label trial included patients with crystal-proven gout who were presented with acute gout flare within 72 h of arthritis onset. Exclusion criteria were advanced renal failure, ongoing ULT, and presence of the HLA-B*5801 allele. Allopurinol was used on days 1 and 14 in early and late groups, respectively. Primary outcome was time to complete arthritis resolution, and secondary outcomes were time to clinical resolution; arthritis relapse; laboratory parameters; and adverse events. RESULTS: One hundred seventeen patients were randomized to early and late allopurinol groups (n = 59 and 58, respectively). One patient in each group was lost to follow-up; therefore, 115 patients were included in the modified intention-to-treat analysis. Baseline characteristics were comparable between the groups. The median time to complete resolution was not significantly different between the early and late allopurinol groups (6 [5-14] and 6 [5-7] days, respectively; p = 0.14). The median time to clinical resolution was 4 [3-6] days in both groups (p = 0.12). Other secondary outcomes were not significantly different. Serious adverse events did not occur in either group. CONCLUSIONS: Early allopurinol initiation during an acute gout flare did not lead to significant changes in time to resolution, flare recurrence, and inflammatory markers. Key Points • Allopurinol Initiation in Gout.
Authors: Timothy Hudson Rainer; Chi Hung Cheng; Hein J E M Janssens; Chi Yin Man; Lai Shan Tam; Yu Fai Choi; Wah Hon Yau; Ka Hing Lee; Colin Alexander Graham Journal: Ann Intern Med Date: 2016-02-23 Impact factor: 25.391
Authors: Jasvinder A Singh; William J Taylor; Nicola Dalbeth; Lee S Simon; John Sundy; Rebecca Grainger; Rieke Alten; Lyn March; Vibeke Strand; George Wells; Dinesh Khanna; Fiona McQueen; Naomi Schlesinger; Annelies Boonen; Maarten Boers; Kenneth G Saag; H Ralph Schumacher; N Lawrence Edwards Journal: J Rheumatol Date: 2013-12-15 Impact factor: 4.666
Authors: Angelo L Gaffo; Nicola Dalbeth; Kenneth G Saag; Jasvinder A Singh; Elizabeth J Rahn; Amy S Mudano; Yi-Hsing Chen; Ching-Tsai Lin; Sandra Bourke; Worawit Louthrenoo; Janitzia Vazquez-Mellado; Hansel Hernández-Llinas; Tuhina Neogi; Ana Beatriz Vargas-Santos; Geraldo da Rocha Castelar-Pinheiro; Rodrigo B C Amorim; Till Uhlig; Hilde B Hammer; Maxim Eliseev; Fernando Perez-Ruiz; Lorenzo Cavagna; Geraldine M McCarthy; Lisa K Stamp; Martijn Gerritsen; Viktoria Fana; Francisca Sivera; William Taylor Journal: Arthritis Rheumatol Date: 2018-02-06 Impact factor: 10.995
Authors: Arrigo F G Cicero; Federica Fogacci; Raffaele Ivan Cincione; Giuliano Tocci; Claudio Borghi Journal: Med Princ Pract Date: 2020-10-09 Impact factor: 1.927
Authors: P Richette; M Doherty; E Pascual; V Barskova; F Becce; J Castañeda-Sanabria; M Coyfish; S Guillo; T L Jansen; H Janssens; F Lioté; C Mallen; G Nuki; F Perez-Ruiz; J Pimentao; L Punzi; T Pywell; A So; A K Tausche; T Uhlig; J Zavada; W Zhang; F Tubach; T Bardin Journal: Ann Rheum Dis Date: 2016-07-25 Impact factor: 19.103